Hyundai Bioscience Co. Ltd Market Cap ($356.42 Million)
Market Cap & Net Worth: Hyundai Bioscience Co. Ltd (048410)
Hyundai Bioscience Co. Ltd market cap. Hyundai Bioscience Co. Ltd (KQ:048410) has a market capitalization of $356.42 Million (₩525.94 Billion) as of November 6, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #13722 globally and #407 in its home market, demonstrating a -6.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hyundai Bioscience Co. Ltd's stock price ₩5450.00 by its total outstanding shares 96503316 (96.50 Million). Also see cash flow conversion of Hyundai Bioscience Co. Ltd for how efficiently the company converts equity into cash flow.
Hyundai Bioscience Co. Ltd Market Cap History (2015–2026)
Hyundai Bioscience Co. Ltd market cap history from 2015 to 2026. Data shows change from $397.63 Million to $356.42 Million (-0.40% CAGR). Check Hyundai Bioscience Co. Ltd (048410) share price today for real-time trading data and today's change.
Index Memberships
Hyundai Bioscience Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$207.23 Billion | 0.17% | #117 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$207.23 Billion | 0.17% | #117 of 1384 |
Weight: Hyundai Bioscience Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Hyundai Bioscience Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hyundai Bioscience Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Hyundai Bioscience Co. Ltd (048410) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.09x
Hyundai Bioscience Co. Ltd's market cap is 0.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $346.61 Million | $36.10 Billion | -$8.07 Billion | 0.01x | N/A |
| 2017 | $344.65 Million | $31.97 Billion | $1.22 Billion | 0.01x | 0.28x |
| 2018 | $354.46 Million | $31.24 Billion | $2.62 Billion | 0.01x | 0.14x |
| 2019 | $918.85 Million | $30.09 Billion | $767.22 Million | 0.03x | 1.20x |
| 2020 | $1.91 Billion | $12.51 Billion | -$8.61 Billion | 0.15x | N/A |
| 2021 | $1.65 Billion | $9.24 Billion | -$20.05 Billion | 0.18x | N/A |
| 2022 | $1.79 Billion | $7.85 Billion | -$15.81 Billion | 0.23x | N/A |
| 2023 | $1.71 Billion | $9.48 Billion | -$14.50 Billion | 0.18x | N/A |
| 2024 | $922.78 Million | $15.05 Billion | -$6.93 Billion | 0.06x | N/A |
| 2025 | $324.71 Million | $3.52 Billion | -$22.13 Billion | 0.09x | N/A |
Competitor Companies of 048410 by Market Capitalization
Companies near Hyundai Bioscience Co. Ltd in the global market cap rankings as of November 6, 2026. Also see balance sheet size of Hyundai Bioscience Co. Ltd for a full breakdown of the balance sheet.
Key companies related to Hyundai Bioscience Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Hyundai Bioscience Co. Ltd (2015–2026)
Market capitalization of Hyundai Bioscience Co. Ltd from 2015 to today. Between 2015 and today, Hyundai Bioscience Co. Ltd's market cap moved from $397.63 Million to $ 356.42 Million, with a yearly change of -0.40%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩356.42 Million | +9.77% |
| 2025 | ₩324.71 Million | -64.81% |
| 2024 | ₩922.78 Million | -45.94% |
| 2023 | ₩1.71 Billion | -4.74% |
| 2022 | ₩1.79 Billion | +8.51% |
| 2021 | ₩1.65 Billion | -13.53% |
| 2020 | ₩1.91 Billion | +107.83% |
| 2019 | ₩918.85 Million | +159.23% |
| 2018 | ₩354.46 Million | +2.85% |
| 2017 | ₩344.65 Million | -0.57% |
| 2016 | ₩346.61 Million | -12.83% |
| 2015 | ₩397.63 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Hyundai Bioscience Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $356.42 Million USD |
| MoneyControl | $356.42 Million USD |
| MarketWatch | $356.42 Million USD |
| marketcap.company | $356.42 Million USD |
| Reuters | $356.42 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hyundai Bioscience Co. Ltd
Hyundai Bioscience Co., Ltd. operates as a biotechnology company. The company provides Vitabrid C12, a vitamin C product that delivers active vitamin C into the skin. It develops Polytaxel, a drug for pancreatic cancer and solid tumors; and CP-COV03 drug for Covid 19. The company was founded in 2000 and is based in Seoul, South Korea.